A BeiGene research and development facility in Beijing. Photo: Bloomberg

Chinese cancer drugs developer BeiGene first to seek secondary flotation in Hong Kong after listing reform

US and Beijing-based company could raise between US$908 million and US$1.07 billion

Topic |   IPO

TOP PICKS

A BeiGene research and development facility in Beijing. Photo: Bloomberg
READ FULL ARTICLE